Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A.

Haemophilia. 2018 Dec 6. doi: 10.1111/hae.13649. [Epub ahead of print]

PMID:
30520534
2.

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A.

BMJ Open. 2018 Aug 8;8(8):e021900. doi: 10.1136/bmjopen-2018-021900.

3.

Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project.

Konkle BA, Johnsen JM, Wheeler M, Watson C, Skinner M, Pierce GF; My Life Our Future programme.

Haemophilia. 2018 May;24 Suppl 6:87-94. doi: 10.1111/hae.13506. Review.

PMID:
29878652
4.

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project.

Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S; coreHEM panel.

Haemophilia. 2018 Jul;24(4):e167-e172. doi: 10.1111/hae.13504. Epub 2018 May 20.

PMID:
29781145
5.

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia.

Skinner MW, Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker JS, Iorio A.

Pilot Feasibility Stud. 2018 Feb 27;4:58. doi: 10.1186/s40814-018-0253-0. eCollection 2018.

6.

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Pierce GF, Ragni MV, van den Berg HM, Weill A, O'Mahony B, Skinner MW, Pipe SW.

Haemophilia. 2017 Sep;23(5):643-644. doi: 10.1111/hae.13313. Epub 2017 Aug 17. No abstract available.

PMID:
28833947
7.

NHF-McMaster Guideline on Care Models for Haemophilia Management.

Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris M, Riker E, Santesso N, Soucie JM, Yeung CH, Iorio A, Sch√ľnemann HJ.

Haemophilia. 2016 Jul;22 Suppl 3:6-16. doi: 10.1111/hae.13008. Review.

PMID:
27348396
8.

Improving comprehensive care in the haemophilia community: building on the HERO Study.

Buzzi A, Kelley L, Gregory M, Skinner M, Kalnins W.

Haemophilia. 2016 Jul;22(4):e320-2. doi: 10.1111/hae.12945. Epub 2016 May 11. No abstract available.

PMID:
27170451
9.

Assessments of outcome in haemophilia - a patient perspective.

O'Mahony B, Skinner MW, Noone D, Page D, O'Hara J.

Haemophilia. 2016 May;22(3):e208-9. doi: 10.1111/hae.12922. Epub 2016 Mar 14. No abstract available.

PMID:
26988632
10.

The national haemophilia program standards, evaluation and oversight systems in the United States of America.

Skinner MW, Soucie JM, Mclaughlin K.

Blood Transfus. 2014 Apr;12 Suppl 3:e542-8. doi: 10.2450/2014.0019-14s. Review. No abstract available.

11.

World Federation of Hemophilia: 50 years of advancing treatment for all.

Skinner MW, Myles E.

Haemophilia. 2013 Jul;19(4):475-80. doi: 10.1111/hae.12200. No abstract available.

PMID:
23777531
12.

Factor VIII products and inhibitors in severe hemophilia A.

Iorio A, Skinner MW, Makris M.

N Engl J Med. 2013 Apr 11;368(15):1456. doi: 10.1056/NEJMc1301995. No abstract available.

PMID:
23574132
13.

Gene therapy for hemophilia: addressing the coming challenges of affordability and accessibility.

Skinner MW.

Mol Ther. 2013 Jan;21(1):1-2. doi: 10.1038/mt.2012.272. No abstract available.

14.

Haemophilia care - past, present and future from a patient perspective.

Skinner MW.

Haemophilia. 2012 Jul;18 Suppl 5:3-5. doi: 10.1111/j.1365-2516.2012.02892.x. No abstract available.

PMID:
22757677
15.

WFH: closing the global gap--achieving optimal care.

Skinner MW.

Haemophilia. 2012 Jul;18 Suppl 4:1-12. doi: 10.1111/j.1365-2516.2012.02822.x.

PMID:
22726075
16.

Ensuring maximum outcomes and benefits in comprehensive care for bleeding disorders through surveillance and data collection.

Skinner MW.

Hematology. 2012 Apr;17 Suppl 1:S147-9. doi: 10.1179/102453312X13336169156573.

PMID:
22507805
17.

Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia.

High KA, Skinner MW.

Mol Ther. 2011 Oct;19(10):1749-50. doi: 10.1038/mt.2011.203. No abstract available.

18.

Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.

Skinner MW.

Br J Haematol. 2011 Sep;154(6):704-14. doi: 10.1111/j.1365-2141.2011.08765.x. Epub 2011 Jun 28. Review.

PMID:
21707577
19.

Global data and haemophilia care trends: commentary.

Skinner M, Street A.

Haemophilia. 2010 Jan;16(1):18-9. doi: 10.1111/j.1365-2516.2009.02177.x. No abstract available.

PMID:
20666846
20.

Building our global family--achieving treatment for all.

Skinner MW.

Haemophilia. 2010 Jul;16 Suppl 5:1-10. doi: 10.1111/j.1365-2516.2010.02285.x.

PMID:
20590849

Supplemental Content

Loading ...
Support Center